Abstract
Purpose To explore the high signal-to-noise ratio (SNR) efficiency of interleaved multi-shot 3D-EPI for fast and robust high-resolution whole-brain quantitative susceptibility (QSM) and 
mapping at 7T and 3T.
Methods Single- and multi-TE segmented 3D-EPI is combined with conventional CAIPIRINHA undersampling for up to 72-fold effective gradient echo (GRE) imaging acceleration. Across multiple averages, scan parameters are varied (e.g. dual-polarity frequency-encoding) to additionally correct for B0-induced artifacts, geometric distortions and motion retrospectively. A comparison to established GRE protocols is made. Resolutions range from 1.4mm isotropic (1 multi-TE average in 36s) up to 0.4mm isotropic (2 single-TE averages in approximately 6 minutes) with whole-head coverage.
Results Only 1-4 averages are needed for sufficient SNR with 3D-EPI, depending on resolution and field strength. Fast scanning and small voxels together with retrospective corrections result in substantially reduced image artifacts, which improves susceptibility and 
mapping. Additionally, much finer details are obtained in susceptibility-weighted image projections through significantly reduced partial voluming.
Conclusion Using interleaved multi-shot 3D-EPI, single-TE and multi-TE data can readily be acquired 10 times faster than with conventional, accelerated GRE imaging. Even 0.4mm isotropic whole-head QSM within 6 minutes becomes feasible at 7T. At 3T, motion-robust and distortion-free 0.8mm isotropic whole-brain QSM and 
mapping in less than 7 minutes becomes clinically feasible. Stronger gradient systems may allow for even higher effective acceleration rates through larger EPI factors while maintaining optimal contrast.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee at the Bonn Medical Faculty, Bonn University Clinics, gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
